10318 results for 'nike inhibitor'

PD-1 & PD-L1 interaction between T-cells and tumour cells. What are PD-1 and PD-L1? PD-1, also known as programmed cell death 1, is a receptor expressed on t

Small molecule inhibitors represent a significant advancement in the field of therapeutic interventions, offering a versatile approach to treating a myriad of diseases, including cancer, viral inf

Enhancing Cancer Research: Syngeneic Mouse Models and Immune Checkpoint Inhibitors A quick guide to Syngeneic Mouse Models Syngeneic Mouse Models Cancer research has seen rema

For decades, the fight against cancer has been a story of incremental gains. But what if we could fundamentally shift the battlefield, turning the body's own immune system into a precision-guided weap

Leukemia Inhibitory Factor (LIF) is a cytokine that plays a crucial role in various physiological processes within the human body. It has gained significant attention in the field of

Leukemia Inhibitory Factor and JAK-STAT Signalling Pathway Leukemia inhibitory factor (LIF) is a cytokine that belongs to the interleukin-6 (IL-6) family of cytokines. Other members of

PD-1 gets the attention, but it is one brake among many — and the others do not work the same way. The co-inhibitory receptors are routinely drawn as interchangeable stop signs on a T cell. They are

The initial identification of PD-1 as a potential target for cancer treatment occurred in the late 1990s and early 2000s through studies exploring the regulation of T-cell responses.

T cell immunoglobulin and mucin-domain containing-3 (TIM-3) is an immune checkpoint receptor that plays a pivotal role in T cell exhaustion, a state where T cells lose their ability to ef

Lymphocyte Activation Gene-3 (LAG-3) is an immune checkpoint receptor that plays a critical role in regulating T cell function. In recent years, LAG-3 has emerged as a potential target fo

The advent of immune checkpoint targeting marks a significant milestone in the oncological field, offering a beacon of hope for patients battling cancer. This innovative approach leverages the bod

In recent years, the field of oncology has witnessed a paradigm shift with the advent of immunotherapy, a treatment modality that harnesses the body's immune system to combat cancer. Among the mos

Cell Signalling · EnzymologyProtein Kinases: Function, Classification, Structure and InhibitorsProtein kinases transfer a phosphate group from ATP onto specific residues of target proteins, switching

Cancer cells are adept at avoiding destruction by the immune system, often exploiting specific pathways to escape detection and elimination. One of these key mechanisms involves the SIRPα

Recent advances in immunotherapy have highlighted the importance of targeting immune checkpoints to enhance the immune system’s ability to combat cancer. A new potential target in this gr

Targeting USP22: A New Approach to Enhance Anticancer Immunity Introduction In the ever-evolving landscape of cancer research, the intricate relationship between immune e

The Role of CTLA-4 in Breast Cancer: Implications for ImmunotherapyBreast cancer (BC) remains one of the most prevalent malignancies affecting women worldwide, with significant morbidity and mortality

Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking

Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio